Varipulse, Johnson & Johnson

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.
Johnson & Johnson announced that on January 5, “out of an abundance of caution,” Johnson & Johnson MedTech temporarily paused the U.S.
The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.
Johnson & Johnson said on Wednesday it has temporarily paused the rollout of its Varipulse heart device in the United States, ...